Literature DB >> 12866342

Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia.

Mythily Subramaniam1, Siow-Ann Chong, Elaine Pek.   

Abstract

OBJECTIVES: This study aimed to establish the prevalence of diabetes mellitus (DM) and impaired glucose tolerance in patients with schizophrenia and to elucidate some of the factors associated with hyperglycemia.
METHODS: We studied a sample of 194 patients with schizophrenia. We determined fasting blood glucose and insulin levels at the start of the testing period; patients were given an oral glucose tolerance test after an overnight fast.
RESULTS: The overall prevalence of diabetes and impaired glucose tolerance in these patients was 16.0% and 30.9%, respectively. These rates were higher than those reported in the general population. Patients with disordered glucose homeostasis were significantly older (P = 0.005, Kruskal-Wallis test). There was no significant effect of sex or ethnicity on diabetes.
CONCLUSIONS: Our findings suggest that patients with schizophrenia are more vulnerable to developing DM. We caution clinicians to be mindful of the increased risk and to be vigilant for such a development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866342     DOI: 10.1177/070674370304800512

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  20 in total

1.  Immunological characteristics of diabetes in schizophrenia.

Authors:  Dan Cohen; M R Batstra; C C Gispen-de Wied
Journal:  Diabetologia       Date:  2005-07-29       Impact factor: 10.122

Review 2.  Antipsychotic drugs and diabetes--an application of the Austin Bradford Hill criteria.

Authors:  R I G Holt; R C Peveler
Journal:  Diabetologia       Date:  2006-05-13       Impact factor: 10.122

Review 3.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

4.  Prevalence and correlates of diabetes mellitus and dyslipidaemia in a long-stay inpatient schizophrenia population in Singapore.

Authors:  Saleha Shafie; Siau Pheng Lee; Samantha Bee Cheng Ong; Peizhi Wang; Esmond Seow; Hui Lin Ong; Siow Ann Chong; Mythily Subramaniam
Journal:  Singapore Med J       Date:  2018-02-12       Impact factor: 1.858

5.  Emergency department utilization among Medicaid beneficiaries with schizophrenia and diabetes: the consequences of increasing medical complexity.

Authors:  Ruth S Shim; Benjamin G Druss; Shun Zhang; Giyeon Kim; Adesoji Oderinde; Sosunmolu Shoyinka; George Rust
Journal:  Schizophr Res       Date:  2013-12-28       Impact factor: 4.939

6.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

7.  Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Authors:  Jaana Suvisaari; Jonna Perälä; Samuli I Saarni; Tommi Härkänen; Sami Pirkola; Matti Joukamaa; Seppo Koskinen; Jouko Lönnqvist; Antti Reunanen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

8.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 9.  Adverse effects of atypical antipsychotics : differential risk and clinical implications.

Authors:  Peter M Haddad; Sonu G Sharma
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  A well-being programme in severe mental illness. Baseline findings in a UK cohort.

Authors:  S Smith; D Yeomans; C J P Bushe; C Eriksson; T Harrison; R Holmes; L Mynors-Wallis; H Oatway; G Sullivan
Journal:  Int J Clin Pract       Date:  2007-12       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.